Article ; Online: Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Scandinavian journal of gastroenterology
2024 Volume 59, Issue 5, Page(s) 553–560
Abstract: Background: Hypersensitivity reactions (HSR) to the administration of infliximab (IFX) in Inflammatory Bowel Diseases (IBD) patients are not rare and usually lead to drug discontinuation. We report data on safety and effectiveness of desensitization to ... ...
| Abstract | Background: Hypersensitivity reactions (HSR) to the administration of infliximab (IFX) in Inflammatory Bowel Diseases (IBD) patients are not rare and usually lead to drug discontinuation. We report data on safety and effectiveness of desensitization to IFX in patients with previous HSR. Methods: We conducted a retrospective monocentric observational study. Patients for whom a desensitization protocol to IFX was realized after a previous HSR were included. Anti-drug antibodies (ADA) and IFX trough levels at both inclusion and six months after desensitization were collected. Clinical outcomes, including recurrence of HSR were evaluated. Results: From 2005 to 2020, 27 patients (Crohn's Disease: 26 (96%) were included). Desensitization after HSR was performed after a median time of 10.4 months (2.9-33.1). Nineteen (70%) patients received immunosuppressants at time of desensitization. Eight (30%) patients presented HSR at first ( Conclusion: IFX desensitization in patients with IBD is a safe therapeutic alternative and represents a potential option for patients refractory to multiple biologics. |
|---|---|
| MeSH term(s) | Humans ; Infliximab/therapeutic use ; Infliximab/administration & dosage ; Infliximab/immunology ; Infliximab/adverse effects ; Female ; Male ; Retrospective Studies ; Adult ; Desensitization, Immunologic/methods ; Drug Hypersensitivity/immunology ; Drug Hypersensitivity/etiology ; Middle Aged ; Gastrointestinal Agents/therapeutic use ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/immunology ; Gastrointestinal Agents/administration & dosage ; Inflammatory Bowel Diseases/drug therapy ; Inflammatory Bowel Diseases/immunology ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Treatment Outcome ; Young Adult |
| Chemical Substances | Infliximab (B72HH48FLU) ; Gastrointestinal Agents |
| Language | English |
| Publishing date | 2024-02-14 |
| Publishing country | England |
| Document type | Journal Article ; Observational Study |
| ZDB-ID | 82042-8 |
| ISSN | 1502-7708 ; 0036-5521 |
| ISSN (online) | 1502-7708 |
| ISSN | 0036-5521 |
| DOI | 10.1080/00365521.2024.2316765 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 567: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.